

AN - 1999-323462 [27]

AP - JP19970291739 19971008

CPY - TOAG

DC - B06

FS - CPI

IC - A61K33/38

MC - B05-A03B B05-B02A3 B14-H01

M2 - [01] A100 A200 A400 A500 A547 A600 A940 A950 B115 B701 B713 B720 B815  
B831 C101 C108 C500 C550 C802 C804 C805 C807 M411 M710 M903 M904 P633;  
9927-BPO01-N 9927-BPO01-T

- [02] A100 A200 A400 A500 A547 A600 A940 A950 B115 B701 B713 B720 B815  
B831 C101 C108 C500 C550 C802 C804 C805 C807 M411 M710 M903 M904 P633;  
9927-BPO02-N 9927-BPO02-T

PA - (TOAG ) TOA GOSEI CHEM IND LTD

PN - JP11116488 A 19990427 DW199927 A61K33/38 003pp

PR - JP19970291739 19971008

XA - C1999-095395

XIC - A61K-033/38

AB - J11116488 Anticancer agent comprises a compound of formula  
 $\text{AgaAbM}_2(\text{PO}_4)_3 \cdot n\text{H}_2\text{O}$ . A = alkaline metal ion, alkaline earth metal ion,  
ammonium ion or hydrogen ion; M = tetravalent metal; n = 0-6 and a +  
mb = 1.

- USE - The agent is administered in a dose of 0.1-500 mg/kg orally or  
by injection.

- ADVANTAGE - The agent has high anticancer ability with low side  
effects.

- (Dwg.0/0)

CN - 9927-BPO01-N 9927-BPO01-T 9927-BPO02-N 9927-BPO02-T

IW - ANTICANCER AGENT CONTAIN SILVER CONTAIN PHOSPHATE COMPOUND

IKW - ANTICANCER AGENT CONTAIN SILVER CONTAIN PHOSPHATE COMPOUND

NC - 001

OPD - 1997-10-08

ORD - 1999-04-27

PAW - (TOAG ) TOA GOSEI CHEM IND LTD

TI - Anticancer agent - contains silver containing phosphate compound

XP-002216956